A secondary analysis of the COORDINATE-Diabetes trial found that up to one-third of patients with Type 2 diabetes and atherosclerotic cardiovascular disease stopped their SGLT-2i or GLP-1RA within 12 months, with cost and side effects among the cited reasons. PICO summary and expert commentary.
Browsing: Cardiovascular Outcomes
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide’s effect in high-risk type 2 diabetes. PICO summary and expert commentary.
Clinical Context First-degree relatives of individuals with premature coronary heart disease (CHD before age 55 in men, 65 in women)…
A within-trial analysis of the PROLIFIC RCT finds a family-based lifestyle programme cost-effective for cardiovascular risk reduction in relatives of premature CHD patients. PICO summary and commentary.
An RCT finds curcumin lowers blood pressure, LDL, and inflammatory markers in type 2 diabetes but does not change HbA1c or glucose. PICO summary and expert commentary.
In the SOGALDI-PEF crossover trial, adding spironolactone to dapagliflozin produced a modest 11% NT-proBNP reduction in HFmrEF/HFpEF, offset by eGFR decline and higher potassium. PICO summary and expert commentary.
A small IVUS study finds statin plus PCSK9 inhibitor drives greater plaque regression than either alone in borderline coronary lesions. PICO summary and expert commentary.
A small mechanistic study finds exenatide plus glucagon doubles myocardial glucose uptake in type 2 diabetes, a proof-of-concept for cardiac metabolic effects. PICO summary and commentary.